Q2FY11 preview for Sun Pharma by centrum,

Visit http://indiaer.blogspot.com/ for complete details 􀂄 􀂄


Sun Pharma (Rating – Under Review)
􀂁 We expect the topline to reduce by 6.8% on a YoY basis (and 21.1% on a QoQ basis) to Rs 11bn,
owing to Sun stopping shipment of Eloxatin and Protonix.
􀂁 This is also expected to impact the EBIDTA margin negatively, bringing it down by 1010bps to
30.7%.
􀂁 Lower revenue and margins are also expected to take its toll on the adjusted PAT, bringing it
down by 32% on a YoY (and 41.3% on a QoQ) basis to Rs3.3bn.